The DOI matches its Crossref record.
Cytochrome P450 Turnover: Regulation of Synthesis and Degradation, Methods for Determining Rates, and Implications for the Prediction of Drug Interactions
Abstract
In vivo enzyme levels are governed by the rates of de novo enzyme synthesis and degradation. A current lack of consensus on values of the in vivo turnover half-lives of human cytochrome P450 (CYP) enzymes places a significant limitation on the accurate prediction of changes in drug concentration-time profiles associated with interactions involving enzyme induction and mechanism (time)-based inhibition (MBI). In the case of MBI, the full extent of inhibition is also sensitive to values of enzyme turnover half-life. We review current understanding of CYP regulation, discuss the pros and cons of various in vitro and in vivo approaches used to estimate the turnover of specific CYPs and, by simulation, consider the impact of variability in estimates of CYP turnover on the prediction of enzyme induction and MBI in vivo. In the absence of consensus on values for the in vivo turnover half-lives of key CYPs, a sensitivity analysis of predictions of the pharmacokinetic effects of enzyme induction and MBI to these values should be an integral part of the modelling exercise, and the selective use of values should be avoided.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Physiologically-Based Pharmacokinetics in Drug Development and Regulatory Science
Rowland, M., Peck, C., & Tucker, G. (2011) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010510-100540 · Cited by 662
Self-citationJamei, M., Dickinson, G. L., & Rostami-Hodjegan, A. (2009) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.24.53 · Cited by 368
Self-citationRostami-Hodjegan, A. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.65 · Cited by 331
Self-citationGrimm, S. W., Einolf, H. J., Hall, S. D., He, K., Lim, H.-K., Ling, K.-H. J., Lu, C., Nomeir, A. A., Seibert, E., Skordos, K. W., et al. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.026716 · Cited by 310
Sjögren, E., Abrahamsson, B., Augustijns, P., Becker, D., Bolger, M. B., Brewster, M., Brouwers, J., Flanagan, T., Harwood, M., Heinen, C., et al. (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2014.02.010 · Cited by 279
Drug interactions evaluation: An integrated part of risk assessment of therapeutics
Zhang, L., Reynolds, K. S., Zhao, P., & Huang, S.-M. (2010) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2009.12.016 · Cited by 125
“Last but not least, the alteration in physiological parameters caused by intrinsic factors and the uncertainties around these parameters can be incorporated in the model to provide more precise predictions (Chien et al., 2003, 2006; Edginton andWillmann, 2008; Jamei et al., 2009a,b; Yang et al., 2008; Vossen et al., 2…”
BackgroundLauschke, V. M., Vorrink, S. U., Moro, S. M. L., Rezayee, F., Nordling, Å., Hendriks, D. F. G., Bell, C. C., Sison‐Young, R., Park, B. K., Goldring, C. E., et al. (2016) · Hepatology · doi:10.1002/hep.28780 · Cited by 121
Almond, L. M., Mukadam, S., Gardner, I., Okialda, K., Wong, S., Hatley, O., Tay, S., Rowland-Yeo, K., Jamei, M., Rostami-Hodjegan, A., et al. (2016) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.066845 · Cited by 101
Self-citationReverse Translation in PBPK and QSP: Going Backwards in Order to Go Forward With Confidence
Rostami‐Hodjegan, A. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.904 · Cited by 90
Self-citationFader, K. A., Nault, R., Kirby, M. P., Markous, G., Matthews, J., & Zacharewski, T. R. (2017) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2017.02.006 · Cited by 48
Adiwidjaja, J., Boddy, A. V., & McLachlan, A. J. (2022) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-021-03266-y · Cited by 14
Minematsu, T., Lee, J., Zha, J., Moy, S., Kowalski, D., Hori, K., Ishibashi, K., Usui, T., & Kamimura, H. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.029280 · Cited by 9
Metadata
- Authors
- Yang, J., Liao, M., Shou, M., Jamei, M., Yeo, K., Tucker, G., & Rostami-Hodjegan, A.
- Venue
- Current Drug Metabolism
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2008-06-01
- Volume
- 9
- Issue
- 5
- Pages
- 384-393
- ISSN
- 1389-2002 (ISSN-L)
- OpenAlex
- W2146591007
- Cited by
- 241
- References
- 0
- FWCI
- 16.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.